← All trials
NCT06371326
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 21, 2023
- Primary completion
- Aug 30, 2024
- Completion date
- Sep 30, 2024
- First posted
- Apr 17, 2024
- Last posted
- Apr 17, 2024
- Enrollment
- 28
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Beijing QL Biopharmaceutical Co.,LtdLead sponsor
- Bengbu Medical CollegeOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.